Framing: compare equivalent, clinician-defined scenarios over a common time horizon. Two current manufacturer examples demonstrate why a single advertised monthly figure is inadequate:
| Published example, reviewed November 17, 2026 | Conditions that affect comparison |
|---|---|
| Zepbound KwikPen through LillyDirect: starting self-pay prices of $299 at 2.5 mg, $399 at 5 mg and $449 at 7.5–15 mg | The higher-dose offer depends on the refill window. The programme defines a month as 28 days and one KwikPen; pen needles require purchase. Eligibility and changeable terms apply. (lilly.com) |
| Wegovy injection through NovoCare: $199 for each of two introductory fills at 0.25 mg and 0.5 mg for qualifying new patients | The offer runs through December 31, 2026; the page lists $349 subsequently for strengths from 0.25 mg through 2.4 mg. A month is one box of four pens. Eligibility and changeable terms apply. (novocare.com) |
These are patient-access examples, not wholesale quotations or a recommendation to substitute one medicine for another.
Put to: Adam Fein and Rae McMahan.
Buyer owner: CFO and procurement.
A good answer should cover: Exact product and presentation; clinician-supplied dose mix; introductory and continuing prices; supply duration; eligibility; dispensing, shipping and administration supplies; failed deliveries; refunds; internal handling; and who pays each item.
Ask specifically about unusable remainder. FDA currently recommends discarding compounded GLP-1 multidose vials within 28 days of first use, including when compounder instructions suggest longer use. Ask clinical and pharmacy reviewers to resolve any conflicting proposal before assigning value to its full nominal contents. (fda.gov)
Follow-up: “Reprice the same cohort after introductory eligibility ends, one refill condition is missed, and unusable remainder is included.”
Evidence to request: A quotation-normalisation workbook with dated terms and visible assumptions. Thirteen 28-day fills cover 364 days; model actual refill dates rather than silently equating four weeks with a calendar month.
Expert quote — reserved: ________________________________________
Explore the table row by row
A working view of the research
Zepbound KwikPen through LillyDirect: starting self-pay prices of $299 at 2.5 mg, $399 at 5 mg and $449 at 7.5–15 mg
- Conditions that affect comparison
- The higher-dose offer depends on the refill window. The programme defines a month as 28 days and one KwikPen; pen needles require purchase. Eligibility and changeable terms apply. (lilly.com)
Sources cited on this page
- lilly.com · Source 1 ↗https://www.lilly.com/lillydirect/zepbound
- novocare.com · Source 2 ↗https://www.novocare.com/hcp/delivery.html
- fda.gov · Source 3 ↗https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss